Each film-coated tablet contains Atorvastatin, 10 mg.
It is used in the treatment of hypercholesterolemia and combined hyperlipidemia.
The patient should be placed on a standard cholesterol-lowering diet before receiving atorvastatin and should continue on this diet during treatment with atorvastatin. Hypercholesterolemia and Mixed Dyslipidermia; the recommended starting dose of atorvastatin is 10 or 20 mg once daily. Patienrs who require a large reduction in LDL-C (more than 45%) may be started at 40mg once daily. The dosage range of atorvastatin is 10 to 80 mg once daily. Atorvastatin can be administered as single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatin, lipid levels should be analyzed within 2-4 weeks and dosage adjusted accordingly. Since the goal of treatment is lower LDL-C, the NCEP recommends that LDK-C levels be used to initiate and assess treatment response only if LDL-C levels are not available should total C be used to monitor therapy. Heterozygous Familia Hypercholesterolemia in pediatric patients (10-17 years of age): The recommended starting dose of atorvastatin is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of theapy. Adjustments should be made at intervals of four weeks or more. Homozygous Familia Hypercholesterolemia: The dosage of atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are unavailable. Or as prescribed by the physician.
Hypersensitivity to any component of this medication. Active liver disease or unexplained persistent elevations of serum transaminases. Atorvastatin is contraindicated in pregnancy, in breastfeeding mothers and in women of child-bearing potential not using adequate contraceptive measures. An interval of one month should be allowed from stopping atorvastatin treatment to conception in the event of planning a pregnancy.
General: Before instituting therapy with atorvastatin, an attempt should be made to control hypercholesterolemia with appropriate diet, exercise and weight reduction in obese patients and to treat other underlying medical problems. Liver Dysfucntion: HMG-CoA reductase inhibitors, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. It is recommended that liver function tests be performed prior to and at 12 weeks.
ASIA PACIFIC – PHILIPPINES
18 Malumanay St.,
Brgy. Sikatuna Village
Diliman Quezon City